ClinicalTrials.gg
CompletedNCT00537238Updated Jan 28, 2021Results posted

Pregabalin Versus Levetiracetam In Partial Seizures

A Phase 3 interventional study of pregabalin and levetiracetam in Partial Seizures, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 73 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
509
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing pregabalin in Seizures — none open to participants now, none under way, none of them phase 3. Pregabalin · Seizures.

Enrollment
4th of 10
509 · median 276
Started
2007
with 2 others
Phase 3
7 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
9 of 10
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 10 studies testing pregabalin in Seizures, this one is the 4th largest by enrollment, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 7th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

None of the 10 studies testing pregabalin in Seizures is open now. The open studies under Seizures, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing pregabalin in Seizures as a file.
02

Study summary

This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.

03

Conditions studied

  • Partial Seizures

Keywords

  • Epilepsies partial
  • Partial Seizure Disorder
  • Complex Partial Seizure Disorder
  • Epilepsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects (male or female) must be > 18 years of age, with a diagnosis of epilepsy with partial seizures, as defined in the International League Against Epilepsy (ILAE) classification of seizures.
  • Partial seizures may be simple or complex, with or without secondary tonic-clonic generalization.
  • Subjects must be have been diagnosed with epilepsy for at least 2 years, and must have been unresponsive to treatment with at least two but no more than five prior antiepileptic drugs (AEDs), and at the time of study enrollment are on stable dosages of 1 or 2 standard AEDs.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, breastfeeding, or intend to become pregnant during the course of the trial will be excluded
  • Subjects with other neurologic illness that could impair endpoint assessment, or subjects with Lennox-Gastaut syndrome, absence seizures, status epileptics within the 12 months prior to trial entry, or with seizures due to an underlying medical illness or metabolic syndrome, will be excluded.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
509 participants (actual)

Study arms

  • Active comparator
    B

    Drug: pregabalin

  • Active comparator
    A

    Drug: levetiracetam

Interventions

  • 300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects

  • 1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Response to Treatment

    Participants who had at least 50% reduction in 28-day seizure rate from baseline to the end of the maintenance phase were considered as responders. The 28-day seizure rate was calculated as number of partial seizures in the period divided by difference of number of days in the period and number of missing diary day entries in the period, multiplied by 28.

    Time frame: Baseline up to Week 16

Secondary outcomes

  1. Percent Change From Baseline in 28 Day Seizure Frequency at Week 16

    The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline.

    Time frame: Baseline, Week 16

  2. Change From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16

    Change was calculated as (proportion of SGTC seizure rate divided by all partial seizure rates during double blind phase) minus (proportion of SGTC seizure rate divided by all partial seizure rates at baseline). Negative values indicated reductions in seizures.

    Time frame: Baseline, Week 16

  3. Percentage of Participants Without Seizures

    Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the maintenance phase. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.

    Time frame: Baseline up to Week 16

  4. Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up

    BPRS-A:18-item clinician rated scale assesses somatic concern,anxiety, emotional withdrawal,conceptual disorganization,hallucinatory behavior(HB), guilt feelings,suspiciousness,disorientation,tension,mannerisms and posturing,grandiosity,depressive mood,hostility,motor retardation,uncooperativeness,unusual thought content,blunted affect,excitement. Items rated on 7-point scale 1 (not reported) to 7 (very severe). Total score=sum of items(range 18-126), core score=sum of conceptual disorganization, suspiciousness, HB, unusual thought content(range 4-28). Higher total/core score=more impairment.

    Time frame: Baseline, Week 7, 10, 13, 16 and Follow-up (Day 7 of taper phase)

  5. Hospital Anxiety and Depression Scale (HADS) Score

    HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline, Week 16

  6. Medical Outcomes Study Sleep Scale (MOS-SS) Score

    Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales:sleep disturbance,snoring,awakened short of breath,sleep adequacy,somnolence (range:0-100);sleep quantity (range:0-24),optimal sleep(yes/no), and 9 item index measures of sleep disturbance provide composite scores:sleep problem summary,overall sleep problem. Except adequacy,optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score\[RS\] minus lowest possible score divided by possible RS range\*100);total score range:0-100;higher score=more intensity of attribute.

    Time frame: Baseline, Week 16

  7. Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.

    Time frame: Baseline, Week 16

07

Results

Posted Jul 11, 2013
Limitations and caveats
Results for BPRS were provided as change in scores at Week 16 compared to baseline instead of absolute scores as per planned analysis.

Participant flow

Participant flow — Overall Study
MilestonePregabalinLevetiracetam
Started254255
Completed titration phase226236
Completed maintenance phase208210
Entered opt blinded continuation phase185195
Completed8082
Not completed174173
Withdrew: Death12
Withdrew: Adverse event3122
Withdrew: Lack of efficacy2021
Withdrew: Lost to follow-up128
Withdrew: Withdrawal by subject5147
Withdrew: Protocol violation1519
Withdrew: Does not meet entrance criteria02
Withdrew: Other4452

Outcome measures

PrimaryProportion of Participants With Response to Treatment

Participants who had at least 50% reduction in 28-day seizure rate from baseline to the end of the maintenance phase were considered as responders. The 28-day seizure rate was calculated as number of partial seizures in the period divided by difference of number of days in the period and number of missing diary day entries in the period, multiplied by 28.

Time frame:
Baseline up to Week 16
Reported as:
Number · proportion of participants
Proportion of Participants With Response to Treatment
proportion of participantsPregabalinLevetiracetam
Proportion of Participants With Response to Treatment0.590.59
Statistical analysis
  • Pregabalin vs Levetiracetam · Difference in proportion: 0.00 · 90% CI -0.08 to 0.09
SecondaryPercent Change From Baseline in 28 Day Seizure Frequency at Week 16

The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline.

Time frame:
Baseline, Week 16
Reported as:
Median · percent change
Percent Change From Baseline in 28 Day Seizure Frequency at Week 16
percent changePregabalinLevetiracetam
Percent Change From Baseline in 28 Day Seizure Frequency at Week 16-53.93 (-100.0 to 533.1)-57.28 (-100.0 to 276.9)
Statistical analysis
  • Pregabalin vs Levetiracetam · Ranked ANCOVA · p = 0.3571 · Median difference: 4.1 · 95% CI -2.6 to 10.9
SecondaryChange From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16

Change was calculated as (proportion of SGTC seizure rate divided by all partial seizure rates during double blind phase) minus (proportion of SGTC seizure rate divided by all partial seizure rates at baseline). Negative values indicated reductions in seizures.

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage of all partial seizure/28days
Change From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16
percentage of all partial seizure/28daysPregabalinLevetiracetam
Baseline (n=107, 111)39.41 ± 38.14138.94 ± 35.870
Change at Week 16 (n=102, 101)3.93 ± 30.1586.33 ± 32.071
SecondaryPercentage of Participants Without Seizures

Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the maintenance phase. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Without Seizures
percentage of participantsPregabalinLevetiracetam
All Partial Seizure19.9 (14.4 to 25.4)27.6 (21.6 to 33.7)
Simple Partial Seizure65.7 (59.1 to 72.2)66.2 (59.8 to 72.6)
Complex Partial Seizure49.3 (42.3 to 56.2)59.0 (52.4 to 65.7)
SGTC Seizure80.6 (75.1 to 86.1)79.0 (73.5 to 84.6)
Statistical analysis
  • Pregabalin vs Levetiracetam · Fisher Exact · p = 0.0822
  • Pregabalin vs Levetiracetam · Fisher Exact · p = 0.9175
  • Pregabalin vs Levetiracetam · Fisher Exact · p = 0.0483
  • Pregabalin vs Levetiracetam · Fisher Exact · p = 0.7139
SecondaryChange From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up

BPRS-A:18-item clinician rated scale assesses somatic concern,anxiety, emotional withdrawal,conceptual disorganization,hallucinatory behavior(HB), guilt feelings,suspiciousness,disorientation,tension,mannerisms and posturing,grandiosity,depressive mood,hostility,motor retardation,uncooperativeness,unusual thought content,blunted affect,excitement. Items rated on 7-point scale 1 (not reported) to 7 (very severe). Total score=sum of items(range 18-126), core score=sum of conceptual disorganization, suspiciousness, HB, unusual thought content(range 4-28). Higher total/core score=more impairment.

Time frame:
Baseline, Week 7, 10, 13, 16 and Follow-up (Day 7 of taper phase)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up
units on a scalePregabalinLevetiracetam
Baseline: Total BPRS-A Score (n=253, 254)27.26 ± 0.5526.09 ± 0.56
Baseline: Core BPRS-A Score (n=253, 254)5.18 ± 0.135.01 ± 0.13
Change at Week 7: Total BPRS-A Score (n=217, 225)-2.16 ± 0.36-1.70 ± 0.36
Change at Week 7: Core BPRS-A Score (n=216, 225)-0.34 ± 0.08-0.22 ± 0.08
Change at Week 10: Total BPRS-A Score (n=217, 219)-2.64 ± 0.37-2.42 ± 0.38
Change at Week 10: Core BPRS-A Score (n=217, 219)-0.40 ± 0.08-0.34 ± 0.08
Change at Week 13: Total BPRS-A Score (n=209, 214)-2.99 ± 0.39-2.68 ± 0.39
Change at Week 13: Core BPRS-A Score (n=209, 214)-0.51 ± 0.07-0.38 ± 0.07
Change at Week 16: Total BPRS-A Score (n=235, 241)-2.70 ± 0.40-1.92 ± 0.40
Change at Week 16: Core BPRS-A Score (n=235, 241)-0.40 ± 0.08-0.26 ± 0.08
Change at Follow-up: Total BPRS-A Score(n=178,189)-2.77 ± 0.44-1.42 ± 0.43
Change at Follow-up: Core BPRS-A Score(n=178,189)-0.37 ± 0.10-0.11 ± 0.10
Statistical analysis
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.1334 · Least squares (ls) mean difference: 1.17 · 95% CI -0.36 to 2.69
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.3551 · Ls mean differences: 0.17 · 95% CI -0.19 to 0.52
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.3638 · Ls mean differences: -0.46 · 95% CI -1.45 to 0.53
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.2457 · Ls mean differences: -0.12 · 95% CI -0.34 to 0.09
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.6640 · Ls mean differences: -0.23 · 95% CI -1.26 to 0.81
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.5950 · Ls mean differences: -0.06 · 95% CI -0.30 to 0.17
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.5701 · Ls mean differences: -0.31 · 95% CI -1.38 to 0.76
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.2452 · Ls mean differences: -0.12 · 95% CI -0.33 to 0.08
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.1697 · Ls mean differences: -0.77 · 95% CI -1.88 to 0.33
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.2283 · Ls mean differences: -0.14 · 95% CI -0.36 to 0.09
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.0262 · Ls mean differences: -1.35 · 95% CI -2.54 to -0.16
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.0495 · Ls mean differences: -0.26 · 95% CI -0.52 to 0.00
SecondaryHospital Anxiety and Depression Scale (HADS) Score

HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Hospital Anxiety and Depression Scale (HADS) Score
units on a scalePregabalinLevetiracetam
Baseline: HADS-A (n=253, 253)7.25 ± 0.267.34 ± 0.27
Baseline: HADS-D (n=253, 253)6.22 ± 0.256.00 ± 0.25
Week 16: HADS-A (n=228, 241)6.32 ± 0.226.06 ± 0.22
Week 16: HADS-D (n=228, 241)5.41 ± 0.225.42 ± 0.22
Statistical analysis
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.8084 · Ls mean differences: -0.09 · 95% CI -0.82 to 0.64
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.5263 · Ls mean differences: 0.22 · 95% CI -0.47 to 0.91
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.4008 · Ls mean differences: 0.25 · 95% CI -0.34 to 0.85
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.9749 · Ls mean differences: -0.01 · 95% CI -0.61 to 0.59
SecondaryMedical Outcomes Study Sleep Scale (MOS-SS) Score

Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales:sleep disturbance,snoring,awakened short of breath,sleep adequacy,somnolence (range:0-100);sleep quantity (range:0-24),optimal sleep(yes/no), and 9 item index measures of sleep disturbance provide composite scores:sleep problem summary,overall sleep problem. Except adequacy,optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score\[RS\] minus lowest possible score divided by possible RS range\*100);total score range:0-100;higher score=more intensity of attribute.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Medical Outcomes Study Sleep Scale (MOS-SS) Score
units on a scalePregabalinLevetiracetam
Baseline: Sleep Disturbance (n=253, 253)27.06 ± 1.4528.10 ± 1.48
Baseline: Snoring (n=253, 254)30.72 ± 2.2532.42 ± 2.29
Baseline: Awaken Short of Breath (n=253, 254)15.72 ± 1.5417.26 ± 1.57
Baseline: Quantity of Sleep (n=252, 252)7.77 ± 0.107.82 ± 0.10
Baseline: Adequacy of Sleep (n=253, 254)62.96 ± 1.7964.40 ± 1.83
Baseline: Somnolence (n=253, 254)34.85 ± 1.4333.77 ± 1.45
Baseline: Sleep Problem Index (9) (n=253, 253)29.62 ± 1.1629.49 ± 1.18
Week 16: Sleep Disturbance (n=230, 241)21.97 ± 1.1623.61 ± 1.17
Week 16: Snoring (n=230, 240)33.77 ± 1.7223.75 ± 1.73
Week 16: Awaken Short of Breath (n=230, 241)15.15 ± 1.4814.27 ± 1.48
Week 16: Quantity of Sleep (n=230, 241)7.89 ± 0.097.75 ± 0.09
Week 16: Adequacy of Sleep (n=230, 241)63.46 ± 1.7266.46 ± 1.73
Week 16: Somnolence (n=230, 241)31.56 ± 1.3332.29 ± 1.34
Week 16: Sleep Problem Index (9) (n=230, 241)26.64 ± 0.9526.00 ± 0.96
Statistical analysis
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.6161 · Ls mean differences: -1.03 · 95% CI -5.08 to 3.01
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.3154 · Ls mean differences: -1.63 · 95% CI -4.83 to 1.56
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.5930 · Ls mean differences: -1.70 · 95% CI -7.94 to 4.54
  • Pregabalin vs Levetiracetam · ANCOVA · p = <0.0001 · Ls mean differences: 10.02 · 95% CI 5.27 to 14.76
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.4807 · Ls mean differences: -1.54 · 95% CI -5.83 to 2.75
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.6708 · Ls mean differences: 0.88 · 95% CI -3.18 to 4.94
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.7574 · Ls mean differences: -0.04 · 95% CI -0.32 to 0.24
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.2615 · Ls mean differences: 0.14 · 95% CI -0.10 to 0.38
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.5703 · Ls mean differences: -1.44 · 95% CI -6.42 to 3.54
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.2160 · Ls mean differences: -2.99 · 95% CI -7.74 to 1.75
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.5952 · Ls mean differences: 1.07 · 95% CI -2.89 to 5.03
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.6984 · Ls mean differences: -0.72 · 95% CI -4.40 to 2.95
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.9389 · Ls mean differences: 0.13 · 95% CI -3.09 to 3.34
  • Pregabalin vs Levetiracetam · ANCOVA · p = 0.6344 · Ls mean differences: 0.64 · 95% CI -2.00 to 3.27
SecondaryPercentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score

MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score
percentage of participantsPregabalinLevetiracetam
Baseline (n=252, 252)56.055.6
Week 16 (n=230, 241)58.350.2
Statistical analysis
  • Pregabalin vs Levetiracetam · Regression, Logistic · p = 0.9285 · Odds ratio (or): 1.016 · 95% CI 0.715 to 1.444
  • Pregabalin vs Levetiracetam · Regression, Logistic · p = 0.0696 · Odds ratio (or): 1.432 · 95% CI 0.972 to 2.110

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—24/254 (9.4%)148/254 (58.3%)
Levetiracetam—24/255 (9.4%)127/255 (49.8%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPregabalinLevetiracetam
ConvulsionNervous system disorders5/2541/255
Weight increasedInvestigations2/2540/255
EpilepsyNervous system disorders1/2542/255
Status epilepticusNervous system disorders1/2542/255
AggressionPsychiatric disorders0/2542/255
Suicide attemptPsychiatric disorders0/2542/255
NeutropeniaBlood and lymphatic system disorders1/2540/255
GastroduodenitisGastrointestinal disorders1/2540/255
AstheniaGeneral disorders1/2540/255
DrowningGeneral disorders1/2540/255
Most frequent other events
Most frequent other events
EventPregabalinLevetiracetam
SomnolenceNervous system disorders83/25476/255
DizzinessNervous system disorders59/25442/255
HeadacheNervous system disorders37/25430/255
Weight increasedInvestigations26/2548/255
NasopharyngitisInfections and infestations24/25419/255
NauseaGastrointestinal disorders5/25415/255
InsomniaPsychiatric disorders5/25415/255

Baseline characteristics

Age, Continuous
Age, Continuous(years)PregabalinLevetiracetamTotal
Mean32.7 ± 11.236.3 ± 12.234.5 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinLevetiracetamTotal
Female134130264
Male120125245
08

Study locations

73 sites
  • Pfizer Investigational Site
    Duffel, B-2570, Belgium
  • Pfizer Investigational Site
    Yvoir, B-5530, Belgium
  • Pfizer Investigational Site
    Kyustendil 2500, Bulgaria
  • Pfizer Investigational Site
    Pernik, 2300, Bulgaria
  • Pfizer Investigational Site
    Plovdiv, 4000, Bulgaria
  • Pfizer Investigational Site
    Ruse 7002, Bulgaria
  • Pfizer Investigational Site
    Sofia, 1113, Bulgaria
  • Pfizer Investigational Site
    Sofia, 1407, Bulgaria
  • Pfizer Investigational Site
    Barranquilla, Atlantico 0, Colombia
  • Pfizer Investigational Site
    Bogota, Cundinamarca 0, Colombia
  • Pfizer Investigational Site
    Montes De Oca, San Jose, Costa Rica
  • Pfizer Investigational Site
    San Jose, Costa Rica
  • Pfizer Investigational Site
    Brno 2, 602 00, Czechia
  • Pfizer Investigational Site
    Brno, 602 00, Czechia
  • Pfizer Investigational Site
    Hradec Kralove 3, 500 03, Czechia
  • Pfizer Investigational Site
    Olomouc, 775 20, Czechia
  • Pfizer Investigational Site
    Ostrava-Trebovice, 772 00, Czechia
  • Pfizer Investigational Site
    Praha 4, 140 59, Czechia
  • Pfizer Investigational Site
    Pribram 8, 26195, Czechia
  • Pfizer Investigational Site
    Rychnov nad Kneznou, 516 01, Czechia
  • Pfizer Investigational Site
    Strasbourg Cedex, 67091, France
  • Pfizer Investigational Site
    Toulouse, 31043, France
  • Pfizer Investigational Site
    Bonn, 53105, Germany
  • Pfizer Investigational Site
    Hamburg, 22083, Germany
  • Pfizer Investigational Site
    Athens, 11521, Greece
  • Pfizer Investigational Site
    Thessaloniki, 57010, Greece
  • Pfizer Investigational Site
    Pune, Maharashtra 411 004, India
  • Pfizer Investigational Site
    Chandigarh, Punjab 160 012, India
  • Pfizer Investigational Site
    Ludhiana, Punjab 141 008, India
  • Pfizer Investigational Site
    Firenze, 50125, Italy
  • Pfizer Investigational Site
    Foggia, 71100, Italy
  • Pfizer Investigational Site
    Pisa, 56126, Italy
  • Pfizer Investigational Site
    Siena, 53100, Italy
  • Pfizer Investigational Site
    Busan, 602-715, Korea, Republic of
  • Pfizer Investigational Site
    Daejeon, 301-721, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 120-752, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 135-710, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 137-701, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Kaunas, 50009, Lithuania
  • Pfizer Investigational Site
    Vilnius, 08661, Lithuania
  • Pfizer Investigational Site
    Distrito Federal, 14269, Mexico
  • Pfizer Investigational Site
    San Luis Potosi, 78223, Mexico
  • Pfizer Investigational Site
    Panama, Panama
  • Pfizer Investigational Site
    Lima, L 11, Peru
  • Pfizer Investigational Site
    Lima, Lima 1, Peru
  • Pfizer Investigational Site
    Tondo, Manila 1000, Philippines
  • Pfizer Investigational Site
    Cebu City, 6000, Philippines
  • Pfizer Investigational Site
    Davao City, 8000, Philippines
  • Pfizer Investigational Site
    Makati City, 1200, Philippines
  • Pfizer Investigational Site
    Manila, 1000, Philippines
  • Pfizer Investigational Site
    Quezon City, 1100, Philippines
  • Pfizer Investigational Site
    Moscow, 107150, Russian Federation
  • Pfizer Investigational Site
    Moscow, 125367, Russian Federation
  • Pfizer Investigational Site
    Moscow, 129128, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 194044, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 194354, Russian Federation
  • Pfizer Investigational Site
    St. Petersburg, 197022, Russian Federation
  • Pfizer Investigational Site
    Donostia, Guipuzcoa 20014, Spain
  • Pfizer Investigational Site
    Alicante, 03010, Spain
  • Pfizer Investigational Site
    Barcelona, 08035, Spain
  • Pfizer Investigational Site
    Cordoba, 14008, Spain
  • Pfizer Investigational Site
    Girona, 17007, Spain
  • Pfizer Investigational Site
    Sevilla, 41071, Spain
  • Pfizer Investigational Site
    Kaohsiung, 807, Taiwan
  • Pfizer Investigational Site
    Taichung, 407, Taiwan
  • Pfizer Investigational Site
    Tainan, 704, Taiwan
  • Pfizer Investigational Site
    Capa, Istanbul 34390, Turkey
  • Pfizer Investigational Site
    Ankara, 06100, Turkey
  • Pfizer Investigational Site
    Cerrahpasa / Istanbul, 34098, Turkey
  • Pfizer Investigational Site
    Caracas, Libertador 1010, Venezuela
  • Pfizer Investigational Site
    Caracas, Miranda 1080-A, Venezuela
09

References and documents

Publications

  • Zaccara G, Almas M, Pitman V, Knapp L, Posner H. Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial. Epilepsia. 2014 Jul;55(7):1048-57. doi: 10.1111/epi.12679. Epub 2014 Jun 5. PubMed 24902473 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2007
First posted
Oct 1, 2007
Start
Oct 2007
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Jul 11, 2013
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00537238
Responsible party
Sponsor
First posted
Oct 1, 2007
Start date
Oct 2007
Primary completion
May 2012
Completion
May 2012
Results posted
Jul 11, 2013
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Levetiracetam

Start the discussion